ES3054794T3 - 4-aminoquinazoline compound - Google Patents

4-aminoquinazoline compound

Info

Publication number
ES3054794T3
ES3054794T3 ES22752855T ES22752855T ES3054794T3 ES 3054794 T3 ES3054794 T3 ES 3054794T3 ES 22752855 T ES22752855 T ES 22752855T ES 22752855 T ES22752855 T ES 22752855T ES 3054794 T3 ES3054794 T3 ES 3054794T3
Authority
ES
Spain
Prior art keywords
methyl
cyclopropyl
oxy
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22752855T
Other languages
English (en)
Spanish (es)
Inventor
Kenichi Kawaguchi
Kazuyuki Kuramoto
Tomoyoshi Imaizumi
Takahiro Morikawa
Mitsuaki Okumura
Sunao Imada
Eiji Kawaminami
Ryo Sato
Yohei Seki
Hisao Hamaguchi
Hiroki Ishioka
Hiroki Fukudome
Ikumi Kuriwaki
Takeyuki Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ES3054794T3 publication Critical patent/ES3054794T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES22752855T 2021-02-15 2022-02-14 4-aminoquinazoline compound Active ES3054794T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 4-アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
ES3054794T3 true ES3054794T3 (en) 2026-02-06

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22752855T Active ES3054794T3 (en) 2021-02-15 2022-02-14 4-aminoquinazoline compound

Country Status (12)

Country Link
US (1) US20240150366A1 (cg-RX-API-DMAC7.html)
EP (1) EP4293025B1 (cg-RX-API-DMAC7.html)
JP (1) JP7725511B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145360A (cg-RX-API-DMAC7.html)
CN (1) CN116867788B (cg-RX-API-DMAC7.html)
AU (1) AU2022219651A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211110A1 (cg-RX-API-DMAC7.html)
ES (1) ES3054794T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009520A (cg-RX-API-DMAC7.html)
PL (1) PL4293025T3 (cg-RX-API-DMAC7.html)
SA (1) SA523450286B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629580B1 (ja) 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
CA3255513A1 (en) * 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
EP4568674A1 (en) * 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
EP4293025B1 (en) 2025-10-29
WO2022173033A1 (ja) 2022-08-18
PL4293025T3 (pl) 2026-02-16
JPWO2022173033A1 (cg-RX-API-DMAC7.html) 2022-08-18
SA523450286B1 (ar) 2024-06-12
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
JP7725511B2 (ja) 2025-08-19
KR20230145360A (ko) 2023-10-17
MX2023009520A (es) 2023-08-24
EP4293025A4 (en) 2025-02-26
US20240150366A1 (en) 2024-05-09
EP4293025C0 (en) 2025-10-29
CN116867788B (zh) 2026-05-26
CN116867788A (zh) 2023-10-10
AU2022219651A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
EP4293025B1 (en) 4-aminoquinazoline compound
JP7440710B1 (ja) G12d変異krasタンパクに作用する複素環化合物
JP7169729B1 (ja) G12d変異krasタンパクの分解を誘導するためのキナゾリン化合物
ES2899871T3 (es) Compuesto de quinazolina
TWI908723B (zh) 含氮雜環類衍生物調節劑、其製備方法和應用
ES2977196T3 (es) Inhibidores de receptor de ERBB
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
JP2025523624A (ja) がんの治療のための方法
CA3255513A1 (en) HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
EP4476220A1 (en) Methods for treatment of cancer
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
CN110872289A (zh) 作为IDO1和/或TDO抑制剂的新颖的8-取代的咪唑并[1,5-a]吡啶
EP2483272A2 (en) Pi3k (delta) selective inhibitors
US20220315597A1 (en) Tricyclic compounds and their use
ES2852123T3 (es) Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina y ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inhibidores de CDK4/6 para tratar p. ej. artritis reumatoide, arteriosclerosis, fibrosis pulmonar, infarto cerebral o cáncer
EP3694860A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
WO2023036156A1 (zh) Dna-pk选择性抑制剂及其制备方法和用途
AU2019348120A1 (en) FGFR4 inhibitor and use thereof
JP2024527044A5 (cg-RX-API-DMAC7.html)
WO2025103502A1 (en) Compounds and methods of treating cancers
AU2018301837A1 (en) Tam kinase inhibitors
TWI894448B (zh) Ctla-4小分子降解劑及其應用
KR20250044876A (ko) G12d 돌연변이체 kras 억제 활성을 갖는 이관능성 화합물을 포함하는 항암제의 조합물